
    
      To explore the novel combination of sirolimus and mycophenolate mofetil (MMF) as graft versus
      host disease (GVHD) prevention in HLA matched related donor blood or marrow transplantation
      (BMT). This study will report the toxicities associated with this drug combination and also
      explore possible correlations between specific blood cell types and antibody production
      during this therapy.
    
  